Evaluación de Complejos Eudragit-Flurbiprofeno. Incremento de la Permeación Transcorneal.

QUINTEROS DANIELA; TARTARA IGNACIO; PALMA SANTIAGO; ALLEMANDI DANIEL

Rosario

Congreso; Reunión anual de la Sociedad Argentina de Farmacología Experimental; 2009

SAFE

ENHANCE OF TRASCORNEAL PERMEATION USING NOVEL EUDRAGIT-FLURBIPROFEN COMPLEXES Quinteros D., Tártara I., Palma S and Allemandi D. Depto de Farmacia, Fac. de Cs Químicas, Ciudad Universitaria,5016.Córdoba.Arg.danielaq@fcq.unc.edu.ar In this study we evaluated the transcorneal permeation in rabbits of novel Eudragit-Flurbiprofen (Eu-Fl) complexes. Two Eu-Fl formulations, 0,1% of Fl in 5% dextrose and saline solutions, were assayed. A commercial product (Tolerane®) and 0,01% of Fl aqueous solution (control) were comparatively studied. We corroborated that a high proportion of Fl was attached to Eu by means of ionic interactions. As consequence of this behaviour, an increase in apparent aqueous solubility of Fl was observed, even at pHs where its solubility is low. Regarding transcorneal permeation experiments, Eu-Fl solutions permeated at slower rate when the acceptor medium was dextrose solution, whereas the permeation rate was higher in saline solution. This was owed to the ion exchange produced as consequence of the replacement of Fl by Cl- that diffused from saline solution. Fl, dissolved in the control solution, permeated the cornea at high rate comparatively to the former, owed mainly to high Eu-Fl affinity in Eu-Fl solutions. In addition, Fl permeation from the later was higher than the commercial formulation. The increase in aqueous compatibility of Fl through the dispersion of complexes seemed to improve the drug permeation through rabbit cornea in “ex vivo” experiments. This could be advantageous in the formulation of ophthalmic solutions containing anti-inflammatory drugs.